Loading...
BANB logo

Bachem Holding AGSWX:BANB Stock Report

Market Cap CHF 4.8b
Share Price
CHF 64.40
My Fair Value
CHF 78
17.3% undervalued intrinsic discount
1Y-21.5%
7D-5.4%
Portfolio Value
​
View

Bachem Holding AG

SWX:BANB Stock Report

Market Cap: CHF 4.8b

Bachem Holding (BANB) Stock Overview

Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. More details

BANB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance3/6
Financial Health6/6
Dividends3/6

Rewards

Earnings are forecast to grow 17.86% per year

Earnings have grown 9.1% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the Swiss market

High level of non-cash earnings


BANB Community Fair Values

Create Narrative

See what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.

BANB logo
Bachem Holding

Building K Production Will Serve Peptide And Oligonucleotide Therapies

Key Takeaways Significant expansion in large-scale manufacturing and process automation positions Bachem for outsized growth and improved margins amid rising demand for peptide and oligonucleotide drugs. Strong long-term customer partnerships and leadership in advanced therapeutics offer recurring, less volatile revenue and structural advantage as biopharma outsourcing intensifies.
View narrative
CHF 77.88
FV
17.3% undervalued intrinsic discount
21.50%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
about 22 hours ago author updated this narrative
BANB logo
Bachem Holding

Expanding Facilities And Secular Trends Will Fuel Peptide Therapeutics Demand

Key Takeaways Rapid facility ramp-ups and integrated process innovations could drive substantial, underestimated margin and efficiency gains, outpacing analyst expectations for growth and profitability. Leadership in advanced peptide and oligonucleotide manufacturing, coupled with regulatory and ESG strengths, uniquely positions Bachem to capture market share and secure recurring revenue.
View narrative
CHF 100.00
FV
35.6% undervalued intrinsic discount
24.92%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
about 21 hours ago author updated this narrative
BANB logo
Bachem Holding

Strict Global Regulation And Rising Costs Will Impede Peptide Capacity

Key Takeaways Intensifying regulations, pricing pressures, and rising competition threaten Bachem's revenue growth, profitability, and ability to maintain premium market positioning. Large capital investments amid uncertain demand risk underutilization, weaker returns, and cash flow constraints if sector innovation or market share trends shift unfavorably.
View narrative
CHF 58.00
FV
11.0% overvalued intrinsic discount
19.42%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
8 days ago author updated this narrative
View Stock Community

Bachem Holding AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Bachem Holding
Historical stock prices
Current Share PriceCHF 64.40
52 Week HighCHF 83.05
52 Week LowCHF 43.34
Beta0.98
1 Month Change-7.47%
3 Month Change24.69%
1 Year Change-21.51%
3 Year Change-2.20%
5 Year Change-14.02%
Change since IPO360.00%

Recent News & Updates

Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly

Aug 16
Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly

Bachem Holding's (VTX:BANB) Profits May Not Reveal Underlying Issues

Jul 30
Bachem Holding's (VTX:BANB) Profits May Not Reveal Underlying Issues

Bachem Holding AG's (VTX:BANB) P/E Is Still On The Mark Following 28% Share Price Bounce

Jul 25
Bachem Holding AG's (VTX:BANB) P/E Is Still On The Mark Following 28% Share Price Bounce

Recent updates

Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly

Aug 16
Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly

Bachem Holding's (VTX:BANB) Profits May Not Reveal Underlying Issues

Jul 30
Bachem Holding's (VTX:BANB) Profits May Not Reveal Underlying Issues

Bachem Holding AG's (VTX:BANB) P/E Is Still On The Mark Following 28% Share Price Bounce

Jul 25
Bachem Holding AG's (VTX:BANB) P/E Is Still On The Mark Following 28% Share Price Bounce

Bachem Holding AG's (VTX:BANB) Share Price Matching Investor Opinion

May 15
Bachem Holding AG's (VTX:BANB) Share Price Matching Investor Opinion

Some Shareholders May Object To A Pay Rise For Bachem Holding AG's (VTX:BANB) CEO This Year

Apr 24
Some Shareholders May Object To A Pay Rise For Bachem Holding AG's (VTX:BANB) CEO This Year

Bachem Holding (VTX:BANB) Will Pay A Larger Dividend Than Last Year At CHF0.85

Apr 11
Bachem Holding (VTX:BANB) Will Pay A Larger Dividend Than Last Year At CHF0.85
User avatar

Building K And 24-Hour Operations Will Improve Efficiency

Capacity expansion and 24/7 operations enhance production, reduce costs, and bolster revenue growth in response to rising demand for peptides and oligonucleotides.

What You Can Learn From Bachem Holding AG's (VTX:BANB) P/E

Dec 29
What You Can Learn From Bachem Holding AG's (VTX:BANB) P/E

Here's Why We Think Bachem Holding (VTX:BANB) Is Well Worth Watching

Nov 10
Here's Why We Think Bachem Holding (VTX:BANB) Is Well Worth Watching

Bachem Holding AG's (VTX:BANB) P/E Still Appears To Be Reasonable

Sep 29
Bachem Holding AG's (VTX:BANB) P/E Still Appears To Be Reasonable

Shareholder Returns

BANBCH Life SciencesCH Market
7D-5.4%-1.3%-0.6%
1Y-21.5%-5.8%-0.6%

Return vs Industry: BANB underperformed the Swiss Life Sciences industry which returned -5.8% over the past year.

Return vs Market: BANB underperformed the Swiss Market which returned -0.6% over the past year.

Price Volatility

Is BANB's price volatile compared to industry and market?
BANB volatility
BANB Average Weekly Movement9.9%
Life Sciences Industry Average Movement4.8%
Market Average Movement3.7%
10% most volatile stocks in CH Market7.6%
10% least volatile stocks in CH Market1.6%

Stable Share Price: BANB's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: BANB's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

FoundedEmployeesCEOWebsite
19712,292Thomas Meierwww.bachem.com

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.

Bachem Holding AG Fundamentals Summary

How do Bachem Holding's earnings and revenue compare to its market cap?
BANB fundamental statistics
Market capCHF 4.83b
Earnings (TTM)CHF 134.19m
Revenue (TTM)CHF 677.93m
36.0x
P/E Ratio
7.1x
P/S Ratio

Is BANB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BANB income statement (TTM)
RevenueCHF 677.93m
Cost of RevenueCHF 466.24m
Gross ProfitCHF 211.69m
Other ExpensesCHF 77.50m
EarningsCHF 134.19m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Mar 12, 2026

Earnings per share (EPS)1.79
Gross Margin31.23%
Net Profit Margin19.79%
Debt/Equity Ratio4.5%

How did BANB perform over the long term?

See historical performance and comparison

Dividends

1.3%
Current Dividend Yield
47%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/28 17:37
End of Day Share Price 2025/08/28 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bachem Holding AG is covered by 24 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas MeyerBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Markus MayerBaader Helvea Equity Research